The global breast cancer therapeutics market size was USD 30.2 billion in 2023, driven by the rising incidence of breast cancer across the globe. The market size is anticipated to grow at a CAGR of 10.8% during the forecast period of 2024-2032 to achieve a value of USD 75.8 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Breast cancer is common in women across the globe and a major reason of cancer related deaths in women. It has been suggested that in USA, over 250,000 fresh cases of invasive breast cancer would be identified in women in 2023, while over forty thousand women are estimated to die of the disease. Breast cancer generally develops in middle-aged and older women. It is noteworthy that men are also prone to breast cancer, though to a very lesser degree. Continual research has led to significant transformation in breast cancer care; procedures such as mastectomy and chemotherapy, along with developments in screening and diagnosis (mammography) and improved disease awareness have considerably enhanced the chances of survival of people suffering from breast cancer.
Symptoms may include lump or thickening feeling dissimilar to surrounding tissue, changes crusting, peeling, or flaking of the pigmented site around the areola or breast skin, pitting or redness of skin over the breast, and others.
Developments in molecular biology, systems biology and genome sciences have offered a deeper understanding of breast cancer at various levels, including genomic, molecular and cellular. Biologically, breast cancer is one of the several types of tumour with multiple factors driving its progression and development.
Companies seek to enhance outcomes of breast cancer patients through scientific innovations and possible path-breaking medicines. Treatments of breast cancer include chemotherapy, surgery, and therapies including biological, hormonal, and radiation. Drugs that have been approved to treat breast cancer include Abemaciclib, Capecitabine, Doxorubicin Hydrochloride, Epirubicin Hydrochloride, Fareston (Toremifene), Gemzar (Gemcitabine Hydrochloride), Halaven (Eribulin Mesylate), and others. Combinations used to treat breast cancer include AC-T, AC, CMF, CAF, FEC, and TAC.
In 2023, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) was afforded Breakthrough Therapy Designation in USA for patients with HER2-low metastatic breast cancer. Such developments are likely to stimulate the global breast cancer therapeutics market.
In 2021, Verzenio® (abemaciclib) was approved by the FDA as the initial and lone CDK4/6 inhibitor for individuals with HR+ HER2- high risk early breast cancer.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By therapy, the market is segmented into:
By cancer type, the market is classified into:
By distribution channel, the market is divided into:
By region, the market is segmented into:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The report extensively analyses major players in the global breast cancer therapeutics market, evaluating their capacity and monitoring latest developments like plant turnarounds, capacity expansions, and mergers and acquisitions:
The EMR report offers deep industry insights through a SWOT analysis and Porter’s Five Forces model.
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Therapy||
|Breakup by Cancer Type||
|Breakup by Distribution Channel||
|Breakup by Route of Administration||
|Breakup by End User||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Breast Cancer Therapeutics Overview
3.1 Guidelines and Stages
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Breast Cancer Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Breast Cancer Epidemiology (2016-2031)
5.3 Europe Breast Cancer Epidemiology (2016-2031)
5.4 Asia-Pacific Breast Cancer Epidemiology (2016-2031)
5.5 Latin America Breast Cancer Epidemiology (2016-2031)
5.6 Middle East & Africa Breast Cancer Epidemiology (2016-2031)
6 Global Breast Cancer Therapeutics Market Overview
6.1 Global Breast Cancer Therapeutics Market Historical Value (2017-2023)
6.2 Global Breast Cancer Therapeutics Market Forecast Value (2024-2032)
7 Global Breast Cancer Therapeutics Market Landscape
7.1 Breast Cancer Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Breast Cancer Therapeutics: Product Landscape
7.2.1 Analysis by Therapy
7.2.2 Analysis by Cancer Type
7.2.3 Analysis by Distribution Channel
7.2.4 Analysis by Route of Administration
7.2.5 Analysis by End User
8 Breast Cancer Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Breast Cancer Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Breast Cancer Therapeutics Market Segmentation
11.1 Global Breast Cancer Therapeutic Market by Therapy
11.1.1 Market Overview
11.1.2 Targeted Therapy
18.104.22.168 Ado-Trastuzumab Emtansine
11.1.3 Hormonal Therapy
22.214.171.124 Selective Estrogen Receptor Modulators (SERMs)
126.96.36.199 Aromatase Inhibitors
188.8.131.52 Estrogen Receptor Downregulators (ERDs)
184.108.40.206 Alkylating Agents
11.2 Global Breast Cancer Therapeutic Market by Cancer Type
11.2.1 Market Overview
11.2.2 Hormone Receptor
11.3 Global Breast Cancer Therapeutic Market by Distribution Channel
11.3.1 Market Overview
11.3.2 Hospital Pharmacies
11.3.3 Retail Pharmacies
11.3.4 Online Pharmacies
11.4 Global Breast Cancer Therapeutic Market by Route of Administration
11.4.1 Market Overview
11.5 Global Breast Cancer Therapeutic Market by End User
11.5.1 Market Overview
11.5.4 Specialty Clinics
11.6 Global Breast Cancer Therapeutics Market by Region
11.6.1 Market Overview
11.6.2 North America
11.6.4 Asia Pacific
11.6.5 Latin America
11.6.6 Middle East and Africa
12 North America Breast Cancer Therapeutics Market
12.1 Market Share by Country
12.2 United States of America
13 Europe Breast Cancer Therapeutics Market
13.1 Market Share by Country
13.2 United Kingdom
14 Asia Pacific Breast Cancer Therapeutics Market
14.1 Market Share by Country
15 Latin America Breast Cancer Therapeutics Market
15.1 Market Share by Country
16 Middle East and Africa Breast Cancer Therapeutics Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.5 South Africa
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Genentech, Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.2 Eli Lilly and Company
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.3 Novartis AG
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.6 Fresenius Kabi
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.7 Astellas Pharma Inc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.8 Oncothyreon Inc
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.9 Genzyme Corporation
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.10 F. Hoffman-La Roche Pvt. Ltd
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.11 AbbVie, Inc.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.12 MacroGenics Inc.
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.13 Onyx Pharmaceuticals, Inc.
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.14 BioNumerik Pharmaceuticals Inc.
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.15 Celldex Therapeutics.
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
24 Breast Cancer Therapeutics - Distribution Model (Additional Insight)
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The breast cancer therapeutics market was valued at USD 30.2 billion in 2023.
The market is expected to grow at a CAGR of 10.8% from 2024 to 2032 to reach a value of USD 75.8 billion by 2032.
The major market drivers are technological advancements and the growing incidence of breast cancer.
The key market trends include increasing investments in research and development, coupled with the launch of several diagnostic and screening programs.
The major regions in the market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
The various therapies of breast cancer therapeutics in the market include targeted therapy, hormonal therapy, and chemotherapy.
The various cancer types of breast cancer therapeutics in the market include hormone receptor and HER2+.
The various distribution channels of breast cancer therapeutics in the market include retail pharmacies, hospital pharmacies, and online pharmacies, among others.
The major players in the market are Eli Lilly and Company, Genentech, Inc., AstraZeneca, Novartis AG, and Sanofi, among others.
Breast cancer is a known as a disease in which cells in the breast grow out of control.
Women who have inherited changes also known as mutations to specific genes, like BRCA1 and BRCA2, are at higher risk of breast and ovarian cancer.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.